CLAIMS

1. Use of a formulation comprising Idursulfase-beta (IDS-β) protein at a concentration ranging from 0.1 mg/ml to 60 mg/ml, Sodium chloride at a concentration of 150 mM, polysorbate 20 at a concentration of 0.05 mg/ml, phosphate at a concentration of 5 mM or less, and having a pH of 6, in the manufacture of a medicament for the treatment of Hunter Syndrome by intracerebroventricular (ICV) administration wherein the medicament is to be intracerebroventricularly administered in a therapeutically effective dose.

2. Use according to claim 1, wherein said formulation comprises Idursulfase-beta (IDS-β) protein at a concentration of 15 mg/ml, Sodium chloride at a concentration of 150 mM, polysorbate 20 at a concentration of 0.05 mg/ml, phosphate at a concentration of 5 mM or less, and has a pH of 6.

3. Use according to claim 1, wherein the medicament is to be intracerebroventricularly administered at a therapeutically effective dose ranging from 1 mg to 30 mg.

4. Use according to claim 1, wherein the medicament is to be intracerebroventricularly administered at a therapeutically effective dose of 10 mg.

5. Use according to claim 1, wherein the medicament is to be intracerebroventricularly administered once every three weeks.

6. Use according to claim 1, wherein the medicament is to be intracerebroventricularly administered once every month.

7. Use according to claim 1, wherein the medicament is to be intracerebroventricularly administered through an intraventricular catheter system comprising a reservoir and a catheter connected to said reservoir.

8. A formulation for use in the treatment of Hunter Syndrome by intracerebroventricular administration comprising Idursulfase-beta (IDS-β) protein at a

concentration ranging from 0.1 mg/ml to 60 mg/ml, Sodium chloride at a concentration of 150 mM, polysorbate 20 at a concentration of 0.05 mg/ml, phosphate at a concentration of 5 mM or less, and having a pH of 6.